Crystalys Therapeutics, Inc. (Crystalys), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, has announced the closing of an oversubscribed US$130 million Series B financing to support the late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout.
Latham & Watkins LLP advised Crystalys in the offering with a corporate team led by San Diego partners Cheston Larson and Christian Hollweg, with associates Alex Stuart-Lovell and Katie Raya.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
